EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real‐world titration, persistence & weight loss of semaglutide and tirzepatide in an academic obesity clinic

Jason M Samuels iD, Fei Ye, Rebecca Irlmeier, Heidi Silver iD, Gitanjali Srivastava, Matthew Spann

Diabetes, Obesity and Metabolism · 2025-11 · 27 (11) · 6200-6209

DOI: 10.1111/dom.70004 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 05.08.2025. Verfasst von Jason M Samuels und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Vanderbilt University Medical Center, Nashville, Tennessee, USA. Hauptthemen laut MEDLINE: Glucagon-Like Peptides, Weight Loss, Obesity, Tirzepatide. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, NCATS NIH HHS, National Center for Advancing Translational Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Trials of the Glucagon‐like Peptide‐1 Receptor Agonists (GLP1RAs) found mean weight losses of 15%–21%, yet realworld dose titration and persistence remain suboptimal, limiting effectiveness. This study aims to determine real‐world titration, persistence and effectiveness of GLP1RAs in patients managed within a multidisciplinary obesity clinic. Materials and Methods This is a singlecentre, retrospective cohort study of patients seen in a multidisciplinary obesity clinic at an academic medical centre from January 2022 to December 2024. Consecutive patients aged 18–75 years enrolled in a ‘no cost to patient’ Medical Weight Loss Bundle program who received ≥1 prescription fill of semaglutide or tirzepatide. Of 2855 enrollees, 2306 (81%) received at least one GLP1RA prescription. The primary outcome was persistence with GLP1RA therapy (continuous prescription fills without a gap ≥84 days). Secondary measures included titration adherence and percentage change in body weight.

Results

Among 2306 patients (median age 46.0 years, Interquartile Ratio [IQR] 38.0–55.0; 85% female; 68% White, 28% Black, 4% Hispanic), with median persistence 10.7 months (IQR 5.4–16.3). Semaglutide was used by 1614 (70%), tirzepatide by 117 (5%), and both agents by 575 (25%). Of semaglutide users, 81% escalated to ≥1 mg and 23% to 2.4 mg; of tirzepatide users, 75% received ≥10 mg and 28% received 15 mg. Among patients persistent for ≥6 months, median weight loss was 9.4% (IQR 6.0%–13.4%); for those persistent for ≥12 months, median weight loss was 14.4% (IQR 9.5%–20.5%).

Conclusions

GLP1RA persistence and dosetitration adherence were moderate but weight loss approximated that seen in clinical trials, supporting real‐world effectiveness.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like PeptidesWeight LossObesityTirzepatideGlucagon-Like Peptide-1 Receptor AgonistsAnti-Obesity AgentsHumansMiddle AgedFemaleMaleAdultRetrospective StudiesAgedYoung AdultAdolescentAcademic Medical CentersTreatment OutcomeHypoglycemic AgentsGlucagon-Like Peptide 1Semaglutide

Stichwörter der Autor:innen

GLP‐1 analogueantiobesity drugincretin therapyreal‐world evidence

Substanzen

Glucagon-Like PeptidesTirzepatideGlucagon-Like Peptide-1 Receptor AgonistsAnti-Obesity AgentsHypoglycemic AgentsGlucagon-Like Peptide 1Semaglutide

Autor:innen und Institutionen

  • Department of Surgery, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
  • Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
  • Department of Public Health Sciences, Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida, USA.
  • Division of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
  • Department of Veterans Affairs, Tennessee Valley Healthcare System, Nashville, Tennessee, USA.
  • Division of Diabetes, Endocrinology & Metabolism, Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.

ORCID-Profile: Jason M Samuels, Heidi Silver

Förderung

  • NIDDK NIH HHS
  • NCATS NIH HHS
  • National Center for Advancing Translational Sciences

Zitieren

APA

Samuels, J. M., Ye, F., Irlmeier, R., Silver, H., Srivastava, G., & Spann, M. (2025). Real‐world titration, persistence & weight loss of semaglutide and tirzepatide in an academic obesity clinic. Diabetes, Obesity and Metabolism, 27(11), 6200-6209. https://doi.org/10.1111/dom.70004

Vancouver

Samuels JM, Ye F, Irlmeier R, Silver H, Srivastava G, Spann M. Real‐world titration, persistence & weight loss of semaglutide and tirzepatide in an academic obesity clinic. Diabetes, Obesity and Metabolism. 2025;27(11):6200-6209. doi:10.1111/dom.70004

BibTeX
@article{Samuels2025,
  author = {Samuels, Jason M and Ye, Fei and Irlmeier, Rebecca and Silver, Heidi and Srivastava, Gitanjali and Spann, Matthew},
  title = {Real‐world titration, persistence & weight loss of semaglutide and tirzepatide in an academic obesity clinic},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2025},
  volume = {27},
  number = {11},
  pages = {6200--6209},
  doi = {10.1111/dom.70004}
}
Kostenlos starten →